ArticleBritish journal of cancer2010
Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Incidence of thrombosis in patients with hepatocellular carcinoma: systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Thrombotic Risk and Coagulation Imbalance in Cirrhosis and Hepatocellular Carcinoma: Clinical Implications and Management.Cancers · 2025Review
- Characterization of lncRNA-Driven Networks in Portal Vein Tumor Thrombosis: Implications for Hepatocellular Carcinoma Progression.Journal of Cancer · 2025Article
- Review
- Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma.Journal of cellular and molecular medicine · 2023Review
- NDRG1 facilitates self-renewal of liver cancer stem cells by preventing EpCAM ubiquitination.British journal of cancer · 2023Article
- Establishment of rat liver cancer cell lines with different metastatic potential.Scientific reports · 2020Article
- Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma.Oncology letters · 2020Article
- 14-3-3ζ binds to and stabilizes phospho-beclin 1Journal of cellular and molecular medicine · 2020Article
- CHML promotes liver cancer metastasis by facilitating Rab14 recycle.Nature communications · 2019Article
- Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β-catenin/TCF/LEF signalling.Cell proliferation · 2019Article
- 14-3-3ζ binds to hepatitis B virus protein X and maintains its protein stability in hepatocellular carcinoma cells.Cancer medicine · 2018Article
- ICAM-1-related long non-coding RNA: promoter analysis and expression in human retinal endothelial cells.BMC research notes · 2018Article
- Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.The oncologist · 2017Article
- Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.EBioMedicine · 2017Article
- Bif-1 promotes tumor cell migration and metastasis via Cdc42 expression and activity.Clinical & experimental metastasis · 2017Article
- Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma.Cancer biology & medicine · 2016Article
- Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement.Oncotarget · 2016Review
- Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPortal vein tumour thrombus (PVTT) is highly associated with the progression and metastasis of hepatocellular carcinoma (HCC). However, there are no appropriate cell models of PVTT with which to study the biological and physiological characteristics of PVTT.
methodsPrimary cell culture was performed by the use of a successive xenograft line called PVTT-#1, which was obtained from a 60-year-old male HCC patient accompanied by PVTT.
resultsA successive cell line named CSQT-2 was established. The cell line showed aggressive phenotypes in terms of cell growth, survival, migration, xenograft and metastasis. Moreover, an orthotopic transplantation assay showed that PVTT can be generated in nude mice when CSQT-2 cells were inoculated in the liver and that it shows a typical migratory tendency in the vascular branches of portal vein. Moreover, the established CSQT-2 cells also showed varied expression of tumour-initiating cell (TIC) markers such as CD133, CD90 and EpCAM.
conclusionEstablishment of CSQT-2 may provide a suitable model with which to investigate the molecular mechanisms of PVTT-related HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.